Please note that following on from information provided to NICE by the company in March 2012, the appraisal of Bortezomib for the treatment of relapsed or refractory follicular non-Hodgkin's lymphoma [ID407] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 407 |
| Referral date | 01 November 2010 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
| 2nd appraisal committee meeting | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | TBC |
| Project manager: | Bijal Joshi |
| Technical Lead: | Raisa Sidhu |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note that following on from information provided to NICE by the company in March 2012, the appraisal of Bortezomib for the treatment of relapsed or refractory follicular non-Hodgkin's lymphoma [ID407] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 22 March 2012 | The technology appraisal has been suspended. This is due to ongoing regulatory discussions regarding the licence for this drug. |
| 2 September 2011 |
Please note that following on from advice received from the manufacturer, this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early March 2012 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid May 2012. |
| 22 February 2011 |
Following on from advice received from the manufacturer, the dates for this appraisal will be confirmed once regulatory approval timelines are established |
For further information on our processes and methods, please see our CHTE processes and methods manual